Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Compressive Dressing and Pharyngocutaneous Fistula After Primary Total Laryngectomy (TIGHT)

15 november 2026 uppdaterad av: Andrea Galli, IRCCS San Raffaele

Impact of Compressive Dressing on the Risk of Pharyngocutaneous Fistula After Primary Total Laryngectomy: A Multicenter Retrospective Observational Study

Pharyngocutaneous fistula (PCF) is one of the most feared complications after total laryngectomy. A compressive neck dressing is often applied after surgery to try to prevent it, but there is no consensus on whether it works or how long it should be kept, and practice varies widely between centers. This multicenter, retrospective, observational study compares the rate of PCF in adult patients with laryngeal squamous cell carcinoma who underwent primary total laryngectomy with direct closure of the hypopharyngeal mucosa and who did or did not receive a postoperative compressive dressing. It also examines whether the duration of the dressing affects the risk of fistula and how fistulas were managed in the two groups. All data are collected from existing medical records; no additional treatment or examination is performed.

Studieöversikt

Detaljerad beskrivning

PCF occurs in about 14% of primary total laryngectomies and about 28% of salvage procedures. It is associated with prolonged hospital stay, higher costs, delayed adjuvant treatment, and further complications. No study has directly compared patients managed with and without a postoperative compressive dressing.

This is a non-profit, multicenter, national, retrospective observational study coordinated by IRCCS Azienda Ospedaliero-Universitaria di Bologna. Consecutive patients who underwent primary total laryngectomy from January 1, 2014 to the study start date are included. All patients were treated according to routine clinical practice at each center. Patients are divided into two groups according to postoperative management: compressive dressing of the cervical region over the neopharyngeal suture (Group A) or no compressive dressing (Group B).

Data are extracted from medical records and entered in pseudonymized form in an electronic case report form (REDCap). Collected variables include demographics, smoking and alcohol use, comorbidities, preoperative laboratory values and inflammatory indices, tumor site and clinical stage, surgical details (neck dissection, thyroidectomy, pharyngeal closure technique, salivary stent, primary voice prosthesis), postoperative antibiotic protocol, time to oral feeding, and fistula characteristics and management.

The planned sample size is 950 patients (475 per group), which provides 80% power to detect a 6.0% difference in fistula rate between groups, assuming a baseline rate of 14.3% in the group without compressive dressing, using a two-sided Fisher's exact test with alpha 0.05. The primary outcome will be analyzed with Fisher's exact test. Secondary outcomes will be analyzed with logistic and linear regression. Confounding will be addressed with propensity score matching, inverse probability weighting, or covariate adjustment, as appropriate.

Studietyp

Observationell

Inskrivning (Beräknad)

950

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

      • Bergamo, Italien
        • Rekrytering
        • ASST Papa Giovanni XXIII
        • Kontakt:
      • Bologna, Italien
        • Rekrytering
        • IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola
        • Kontakt:
          • Edoardo Serafini, Medical Degree
          • Telefonnummer: +39 051 2145263
      • Bologna, Italien
        • Rekrytering
        • Ospedale Maggiore Carlo Alberto Pizzardi
        • Kontakt:
      • Bolzano, Italien
        • Rekrytering
        • Ospedale Centrale di Bolzano
        • Kontakt:
          • Luca Calabrese, medical degree
          • Telefonnummer: +39 0471 438641
          • E-post: orlbz@sabes.it
      • Brescia, Italien
        • Rekrytering
        • ASST degli Spedali Civili di Brescia
        • Kontakt:
      • Candiolo, Italien
        • Rekrytering
        • IRCCS Istituto di Candiolo - Fondazione del Piemonte per l'Oncologia
        • Kontakt:
      • Cesena, Italien
      • Florence, Italien
        • Rekrytering
        • Azienda Ospedaliero-Universitaria Careggi
        • Kontakt:
          • Giandomenico Maggiore, Medical Degree
          • Telefonnummer: +39 055 7942000
      • Forlì, Italien
        • Rekrytering
        • Ospedale G.B. Morgagni - L. Pierantoni
        • Kontakt:
      • Milan, Italien
      • Milan, Italien
      • Modena, Italien
        • Rekrytering
        • Azienda Ospedaliero-Universitaria Policlinico di Modena
        • Kontakt:
      • Naples, Italien
      • Padova, Italien
        • Rekrytering
        • Azienda Ospedale-Università di Padova
        • Kontakt:
      • Pavia, Italien
        • Rekrytering
        • Fondazione IRCCS Policlinico San Matteo
        • Kontakt:
      • Pescara, Italien
      • Ravenna, Italien
      • Reggio Emilia, Italien
        • Rekrytering
        • Arcispedale Santa Maria Nuova
        • Kontakt:
      • Rimini, Italien
      • Roma, Italien
      • Roma, Italien
      • Roma, Italien
      • Torino, Italien
        • Rekrytering
        • AOU Città della Salute e della Scienza (Molinette)
        • Kontakt:
      • Trieste, Italien
        • Rekrytering
        • Ospedale di Cattinara
        • Kontakt:
          • Giancarlo Tirelli, Medical Degree
          • Telefonnummer: +39 040 3994933
          • E-post: tirellig@units.it
      • Verona, Italien
        • Rekrytering
        • Azienda Ospedaliera Universitaria Integrata di Verona
        • Kontakt:
      • Vittorio Veneto, Italien
        • Rekrytering
        • Ospedale di Vittorio Veneto - ULSS 2 Marca Trevigiana
        • Kontakt:

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

N/A

Kön som är behöriga för studier

Allt

Testmetod

Icke-sannolikhetsprov

Studera befolkning

Consecutive adult patients with squamous cell carcinoma of the larynx who underwent primary total laryngectomy with direct closure of the hypopharyngeal mucosa at the participating Italian otolaryngology centers from January 1, 2014 to the study start date.

Beskrivning

Inclusion Criteria:

  • Squamous cell carcinoma of the larynx treated with primary total laryngectomy
  • Primary closure of the hypopharyngeal mucosa
  • Age 18 years or older
  • Informed consent to study participation and to personal data processing
  • Availability of data on comorbidities, laboratory parameters, and postoperative management

Exclusion Criteria:

  • Salvage total laryngectomy
  • Previous radiotherapy or chemoradiotherapy to the head and neck
  • Previous open surgery of the pharyngolaryngeal region
  • Reconstruction with a free or pedicled flap (inlay or onlay)

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiv: RETROSPECTIVE

Kohorter och interventioner

Grupp / Kohort
Intervention / Behandling
Compressive dressing (Group A)

Patients who received a postoperative compressive dressing of the cervical region over the neopharyngeal suture after primary total laryngectomy, according to routine clinical practice at the treating center.

Postoperative compressive dressing applied to the cervical region over the neopharyngeal suture. This is an exposure observed in routine clinical practice; it is not assigned by the study.

No compressive dressing (Group B)

Patients who did not receive a postoperative compressive dressing after primary total laryngectomy, according to routine clinical practice at the treating center.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Incidence of pharyngocutaneous fistula
Tidsram: During the postoperative hospital stay (from surgery to discharge), up to 60 days

Number and percentage of patients who develop a pharyngocutaneous fistula in each group (compressive dressing vs no compressive dressing).

During the postoperative hospital stay (from surgery to discharge), up to 60 days

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Incidence of pharyngocutaneous fistula by duration of compressive dressing
Tidsram: During the postoperative hospital stay (from surgery to discharge), up to 60 days

Number and percentage of patients in Group A who develop a pharyngocutaneous fistula, stratified by duration of the compressive dressing (days).

During the postoperative hospital stay (from surgery to discharge), up to 60 days
Time to onset of pharyngocutaneous fistula
Tidsram: During the postoperative hospital stay (from surgery to discharge), up to 60 days

Number of days from surgery to diagnosis of pharyngocutaneous fistula in each group.

During the postoperative hospital stay (from surgery to discharge), up to 60 days
Type of management of pharyngocutaneous fistula
Tidsram: During the postoperative hospital stay (from surgery to discharge), up to 60 days

Number and percentage of patients with fistula managed conservatively (compressive dressing) or surgically in each group.

During the postoperative hospital stay (from surgery to discharge), up to 60 days
Resolution of pharyngocutaneous fistula
Tidsram: During the postoperative hospital stay (from surgery to discharge), up to 60 days

Number and percentage of patients whose fistula resolved, by initial group and type of management.

During the postoperative hospital stay (from surgery to discharge), up to 60 days
Time to resolution of pharyngocutaneous fistula
Tidsram: During the postoperative hospital stay (from surgery to discharge), up to 60 days

Number of days from diagnosis to resolution of the fistula, by initial group and type of management.

During the postoperative hospital stay (from surgery to discharge), up to 60 days

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Edoardo Serafini, Medical Degree, IRCCS Azienda Ospedaliero-Universitaria di Bologna

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

5 maj 2025

Primärt slutförande (Beräknad)

5 januari 2027

Avslutad studie (Beräknad)

31 mars 2027

Studieregistreringsdatum

Först inskickad

15 november 2026

Först inskickad som uppfyllde QC-kriterierna

15 november 2026

Första postat (Faktisk)

19 november 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

19 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

15 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

De-identified individual participant data underlying the published results will be made available upon reasonable request to the Principal Investigator.

Tidsram för IPD-delning

After publication of the study results in a peer-reviewed journal.

Kriterier för IPD Sharing Access

Data will be shared with researchers who submit a motivated request to the Principal Investigator of the coordinating center (IRCCS Azienda Ospedaliero-Universitaria di Bologna).

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera